1. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.
Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. A. Susceptibility of 32D, C2, and C4 cells to death induced by 18 hours of treatment with 7.5 μg/mL (12.7 μmol/L) etoposide, 100 μmol/L H2O2, or 25 μmol/L Ara-C as measured by PI uptake and flow cytometry. B and C. Proliferation of 32D, C2, and C4 cells incubated with curcumin. B. MTT assay. Cells were treated with 5, 10, or 20 μmol/L curcumin for 18 hours or pretreated for 1 hour with 50 μmol/L zVAD.fmk alone or followed by 20 μmol/L curcumin. Proliferation was estimated by the MTT assay and calculated as the percentage of control. **, P < 0.001; ***, P < versus untreated (Student's t test). C. BrdUrd incorporation. Cells were incubated with 20 μmol/L curcumin for 6 hours and BrdUrd was added for 15 minutes. Cells were fixed, immunostained, and analyzed by flow cytometry. D. Viability of curcumin-treated cells measured by PI uptake and flow cytometry. Cells were treated with 20 μmol/L curcumin and analysis was done at indicated time points. Columns, mean (n = 3); bars, SD.
Kamila Wolanin et al. Mol Cancer Res 2006;4:
©2006 by American Association for Cancer Research